A Phase 3 interventional study of sildenafil and sildenafil in Hypertension, Pulmonary, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 68 sites in 23 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies testing sildenafil in Hypertension, Pulmonary — 1 open to participants now, 1 under way, none of them phase 3. sildenafil · Hypertension, Pulmonary.
Among the 51 studies testing sildenafil in Hypertension, Pulmonary, this one is the 2nd largest by planned enrollment of the 50 interventional ones that give a count, is one of 2 that started in 2002, is one of 15 in phase 3, and was the 15th registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 244 are open to participants now.
Browse Hypertension, Pulmonary studies →1 of the 51 studies testing sildenafil in Hypertension, Pulmonary is open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
By country, each count listing its studies:
sildenafil: first FDA approval 1998 (VIAGRA), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 164 Hypertension, Pulmonary studies recruiting now, 99 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 20 · Phase 4 13
First in 2002; this study’s year is marked. 2 started in 2002.
This study's planned enrollment of 275 is above the median of 35 across 650 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 30 across the 50 interventional studies. Of the 36 that completed or were terminated, 16 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 51 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
10 studies in Hypertension, Pulmonary by Viatris Inc.: none open now, none under way, none of them phase 3. Of 10 finished, 7 (70%) have results posted.
Among the 10 studies in Hypertension, Pulmonary by Viatris Inc., this one is one of 2 that started in 2002, is one of 4 in phase 3, and was the 4th registered.
Viatris Inc.’s Hypertension, Pulmonary studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 51 studies testing sildenafil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Viatris Inc.’s 10 in Hypertension, Pulmonary:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of three doses of oral sildenafil (20, 40 and 80 mg three times a day [TID]) on exercise capacity, as measured by the 6-Minute Walk test, as well as the safety and tolerability, after 12 weeks of treatment in subjects with pulmonary arterial hypertension who are aged 18 years and over. To investigate the plasma concentration-effect relationship and to determine the population pharmacokinetic (PK) parameters.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Included patients had primary pulmonary arterial hypertension, pulmonary hypertension secondary to connective tissue disease, or pulmonary hypertension with surgical repair at least 5 years previously; a mean pulmonary artery pressure greater than or equal to 25 mmHg and a pulmonary artery wedge pressure of less than or equal to 15 mmHg at rest, via right heart catheterisation within 21 days prior to randomisation; and a baseline 6-Minute Walk test distance of 100 m to 450 m.
Exclusion Criteria:
Subjects with congenital heart disease, pulmonary hypertension due to thromboembolism, , chronic obstructive airway disease, congestive heart failure or schistosomiasis; subjects with significant (ie > 2+) valvular disease other than tricuspid regurgitation or pulmonary regurgitation; and acutely decompensated heart failure within the previous 30 days; subjects with pulmonary hypertension secondary to any other etiology other than those specified in the inclusion criteria.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: sildenafil
Drug: sildenafil
Drug: sildenafil
Drug: placebo
sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test).
Time frame: Week 12
Change from baseline in mean pulmonary arterial pressure
Time frame: Week 12
Time from randomisation to the first occurrence of clinical worsening (death or lung transplantation or hospitalisation due to pulmonary hypertension or initiation of prostacyclin therapy or initiation of bosentan therapy)
Time frame: Week 0 to 12
Change from baseline in the BORG dyspnoea score
Time frame: Week 12
Change from baseline in pulmonary hypertension criteria for functional capacity and therapeutic class
Time frame: Week 12
Change from baseline in the 8 dimensions of SF-36 (Physical functioning, Role functioning, Bodily pain, General health, Vitality, Social functioning, Mental health and Reported health transition)
Time frame: Week 4 and Week 12
Change from baseline at Weeks 4 and 12 in the 5 dimensions of ED5Q (Mobility, Self care, Usual Activities, Pain/Discomfort and Anxiety/Depression)
Time frame: Week 4 and Week 12
Patient overall preference assessment
Time frame: Week 12
Change in Chronic Use of Background Therapy for Pulmonary Arterial Hypertension
Time frame: throughout the study
Change from baseline in hemodynamic parameters
Time frame: Week 12
The record gives a start of Oct 2002 and a completion of Nov 2003. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sildenafil
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →